Finance

Novartis rescinds rights to to develop and commercialize multi-tyrosine kinase inhibitor dovitinib due to a material breach by Allarity for lack of financial payment.

The company also announced that it has submitted its new glucose monitoring system to the FDA for approval.

There’s reason to believe that a positive pivot may be in the offing.

Express Scripts has announced plans to offer to a new pharmacy network cost-based pricing option for prescription medications and pharmacy services.

Could the sector please get a little ‘rate’ relief?

Payers won’t let these products break the bank.

When you know it is coming—but it takes forever to get there.

Strong economic data in other sectors mean rising ‘real’ rates.

Could the sector be nearing a turning point in performance?

New executive brings over 30 years of experience in the biopharma industry.

But will Washington’s dealmaking stance upend the momentum?

Conditions require a disciplined approach to drug pricing.

The Medicare Part D cap won’t solve need for financial assistance.

Such a scenario is one possibility as the bear market languishes on.

When deciding on the right commercialization model, organizations must consider multiple factors, including the asset or platform they possess, the launch timing, the funding required, and staffing expertise.

The ‘blistering’ pace may further divide the haves from the have-nots.

Over two years into a bear market, it still can’t catch a sustainable bid.

Experts from Kallyope share biotech challenges they have faced and overcome as well as ways to go about securing funds in this exclusive Q&A.

Looking at corporate value through a portfolio lens provides an astute and reliable path to genuine value creation.

While industry financial markets continued to experience subdued dollar volumes in 2022, dealmaking held steady—with factors such as pharma pursuing strategic priorities and biotech funding woes playing major roles.

Is stock market outperformance for biotech still in the cards for 2023?

According to the 2023 State of Revenue Report, pharma companies are prioritizing digital transformation while struggling with inflation and supply chain disruptions.

Chronicling the market’s rise and fall—and signs of potential recovery.

What a changing economy and related trends could mean for 2023.

Will biopharma investment heat up and signal better fortunes for 2023?

Focus is on cash: who’s got it, who doesn’t, and what will it mean?

Big pharma’s finicky appetite for M&A comes as valuations of sellers soften. Though the pace of deals has picked up some, predicting just how long both sides will hold tight remains difficult.

As fundamentals improve, potential rate plateau could ignite growth.

Rotz discusses a report he co-authored for PwC about how life sciences companies perform on the S&P 500.

Our latest metrics tally across seven business-key measures uncovers some familiar players pacing the field in delivering shareholder value and getting the most from their investments.